Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Repligen Corporation(RGEN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RGEN
10/08/2026: RGEN (2-star) is a SELL. SELL for 1 day. Simulated Profits (3.31%). Updated daily EoD!
Repligen Corporation is a specialized life sciences tools company providing essential components for the manufacturing of biological drugs. The company has a leading position in niche bioprocessing segments such as chromatography and filtration, which historically support high-margin, recurring revenue streams. Its primary growth opportunity lies in the expanding demand for complex biological therapies and the adoption of modern, automated bioprocessing workflows. However, the company faces risks related to biopharma capital expenditure cycles, high valuation multiples, and competition from large, diversified life sciences firms. Repligen is best suited for growth-oriented investors and should be monitored for recovery trends in biopharma manufacturing.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company operates in the high-growth bioprocessing sector with a track record of expanding its market share. |
| Momentum investor | Mixed fit | Momentum depends on a sustained industry upturn in biopharma manufacturing demand. |
| Value investor | Weak fit | Repligen often trades at a high P/E multiple consistent with growth-oriented biotech tools firms. |
| Dividend investor | Weak fit | The company does not currently pay a dividend and reinvests all cash flow into growth. |
| Low-risk investor | Weak fit | High valuation multiples and sensitivity to biopharma cycles lead to significant stock price volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to significant swings based on biopharma sector sentiment. |
| Valuation risk | Medium / high | High growth expectations are priced into the stock, leaving little margin for error. |
| Competition risk (Diversified life sciences giants) | Medium | Larger companies with broader portfolios can bundle products and pressure pricing. |
| Business quality | Strong | The company possesses high-quality recurring revenue from consumables and a defensible niche. |
| Dividend income | Low / none | Investors should not expect income generation from this holding. |
| Execution risk | Medium | Successfully integrating future acquisitions is vital to maintaining growth. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -8.37% | Avg. Invested days 38 | Today’s Advisory SELL |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/08/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.62B USD | Price to earnings Ratio 238.89 | 1Y Target Price 194.95 |
Price to earnings Ratio 238.89 | 1Y Target Price 194.95 | ||
Volume (30-day avg) 1.2M shares | Beta 1.08 | 52 Weeks Range 100.99 - 198.87 | Updated Date 10/08/2026 |
52 Weeks Range 100.99 - 198.87 | Updated Date 10/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.7 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Consumables | Resins, filters, and membranes used repeatedly in manufacturing. | The vast majority of revenue is recurring, which is excellent for long-term stability. |
| Equipment | Chromatography systems and sensors. | These are capital sales that lead to long-term demand for the company's consumables. |
| Geography | North America, Europe, and Asia-Pacific sales. | Global exposure provides a hedge against regional biopharma slowdowns. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE 238.89 | Forward PE 67.11 | Enterprise Value 10.29B | Price to Sales(TTM) 13.52 |
Enterprise Value 10.29B | Price to Sales(TTM) 13.52 | ||
Enterprise Value to Revenue 11.72 | Enterprise Value to EBITDA 53.61 | Shares Outstanding 63.49M | Shares Floating 53.47M |
Shares Outstanding 63.49M | Shares Floating 53.47M | ||
Percent Insiders 4.66 | Percent Institutions 106.22 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.